These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25663152)

  • 21. Preference-based measures in economic evaluation in health care.
    Neumann PJ; Goldie SJ; Weinstein MC
    Annu Rev Public Health; 2000; 21():587-611. PubMed ID: 10884966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of qualitative methods in developing the descriptive systems of preference-based measures of health-related quality of life for use in economic evaluation.
    Stevens K; Palfreyman S
    Value Health; 2012 Dec; 15(8):991-8. PubMed ID: 23244799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of contemporaneous responses for EQ-5D-3L and Minnesota Living with Heart Failure; a case for disease specific multiattribute utility instrument in cardiovascular conditions.
    Kularatna S; Byrnes J; Chan YK; Carrington MJ; Stewart S; Scuffham PA
    Int J Cardiol; 2017 Jan; 227():172-176. PubMed ID: 27865116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in the measurement of health utilities in published cost-utility analyses.
    Brauer CA; Rosen AB; Greenberg D; Neumann PJ
    Value Health; 2006; 9(4):213-8. PubMed ID: 16903990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. QALYs and mental health care.
    Chisholm D; Healey A; Knapp M
    Soc Psychiatry Psychiatr Epidemiol; 1997 Feb; 32(2):68-75. PubMed ID: 9050347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new and more robust test of QALYs.
    Doctor JN; Bleichrodt H; Miyamoto J; Temkin NR; Dikmen S
    J Health Econ; 2004 Mar; 23(2):353-67. PubMed ID: 15019761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient and general public preferences for health states: A call to reconsider current guidelines.
    Versteegh MM; Brouwer WBF
    Soc Sci Med; 2016 Sep; 165():66-74. PubMed ID: 27497260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should "standard gamble" and "'time trade off" utility measurement be used more in mental health research?
    Flood C
    J Ment Health Policy Econ; 2010 Jun; 13(2):65-72. PubMed ID: 20919593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
    Pickard AS; Wang Z; Walton SM; Lee TA
    Health Qual Life Outcomes; 2005 Mar; 3():11. PubMed ID: 15748287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are guidelines for measurement of quality of life contrary to patient-centred care?
    Disher T; Beaubien L; Campbell-Yeo M
    J Adv Nurs; 2018 Nov; 74(11):2677-2684. PubMed ID: 30109711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].
    Wasem J; Hessel F; Kerim-Sade C
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S12-20. PubMed ID: 11533902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality-adjusted life years in cancer: pros, cons, and alternatives.
    Woodward RM; Menzin J; Neumann PJ
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):12-9. PubMed ID: 22966947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
    Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
    Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unchained melody: revisiting the estimation of SF-6D values.
    Craig BM
    Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring utilities of severe facial disfigurement and composite tissue allotransplantation of the face in patients with severe face and neck burns from the perspectives of the general public, medical experts and patients.
    Chuback J; Yarascavitch B; Yarascavitch A; Kaur MN; Martin S; Thoma A
    Burns; 2015 Nov; 41(7):1524-31. PubMed ID: 26068209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported outcomes in cystic fibrosis.
    Goss CH; Quittner AL
    Proc Am Thorac Soc; 2007 Aug; 4(4):378-86. PubMed ID: 17652505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.